Global Treatment Approaches Part 1: Neuroprotection and Stem Cell Therapy

Area of Science:

• Ophthalmology
• Regenerative Medicine
• Gene Therapy

Background:

• Retinal degenerations involve photoreceptor and retinal pigment epithelium (RPE) cell stress, dysfunction, and death.
• Gene-specific therapies target individual genetic causes, incurring high R&D costs and benefiting limited patient populations.
• A significant unmet need exists for treatments applicable to a broader range of retinal degeneration patients.

Purpose of the Study:

• To define and categorize global treatment approaches for retinal degenerations.
• To highlight the potential of gene-agnostic therapies as a scalable treatment strategy.
• To discuss the advantages of gene-agnostic treatments over gene-specific therapies.

Main Methods:

• Literature review and conceptual framework development for classifying global treatment strategies.
• Analysis of existing and emerging therapeutic modalities for retinal degenerations.
• Comparison of gene-agnostic and gene-specific treatment paradigms based on scope and patient applicability.

Main Results:

• Global treatments address common pathophysiologic pathways in retinal degenerations, such as cellular stress and death.
• These strategies are categorized into those that maintain/replace cells (neuroprotection, stem cells) and those that circumvent photoreceptor dysfunction (implants, optogenetics).
• Gene-agnostic therapies offer a wider reach, potentially benefiting patients with unidentified genetic causes and reducing overall treatment development costs.

Conclusions:

• Gene-agnostic therapies represent a significant advancement in managing retinal degenerations.
• Their ability to target common disease mechanisms offers a more inclusive and potentially cost-effective therapeutic avenue.
• Further research and development in gene-agnostic approaches are crucial for addressing the broad spectrum of retinal degenerative diseases.